Disease relevance of Blocadren

• Timolol GFS 0.5% is a safe and effective therapy for open-angle glaucoma or ocular hypertension and is both clinically and statistically equivalent to Timoptic XE 0.5% in reducing intraocular pressure [1].
• Timolol maleate (blocadren) in the treatment of hypertension [2].
• METHODS: Fifteen eyes with open angle glaucoma (OAG) and 12 eyes with ocular hypertension (OH), in the same number of patients, all untreated and newly detected, were examined with colour Doppler imaging of retrobulbar vessels before and after 1 month of topical timolol treatment (0.5% Timoptic BID) [3].
• Attempt to retard growth of the eye in 4 young rabbits by means of prolonged ocular hypotony maintained by timolol-maleate were not successful [4].

High impact information on Blocadren

• Comparison of the postoperative intraocular pressure with Betagan, Betoptic, Timoptic, Iopidine, Diamox, Pilopine Gel, and Miostat [5].
• The rate of epithelial wound closure was slowed, and epithelial DNA content was less in both Timoptic- and vehicle-treated corneas [6].
• Light microscopy showed that the epithelium of animals treated with either Timoptic or vehicle processed fewer cellular layers in the wounded areas as well as considerable disruption of the epithelial layer [6].
• The effect of iontophoresis on corneal permeation of the relatively more hydrophilic TM was much greater than the effect on the more lipophilic BX [7].
• Ultrastructural changes of the rabbit corneal epithelium and endothelium after Timoptic treatment [8].

Biological context of Blocadren

• Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium [9].

Anatomical context of Blocadren

• By the 16th day following ulceration SEM examination revealed the Timoptic treated group had extensive epithelial cell desquamation, as well as hole formation and plasma membrane disruption [10].

Associations of Blocadren with other chemical compounds

• A similar percentage of patients in the Timolol GFS 0.5% group (71%) and Timoptic XE group (72%) had clinically relevant reductions in intraocular pressure [1].
• Recently, ongoing clinical comparison trials of up to three years in length have reported sustained intraocular pressure (IOP) lowering efficacy with brimonidine 0.2% b.i.d., which was comparable with timolol 0.5% (Timoptic; Merck & Co.), accompanied by a favourable tolerability and safety profile [11].
• The pH changes after Timoptol, Xalatan and Pilocarpine showed a similar time pattern and after return to the baseline values the pH shifted to alkaline levels [12].

References